Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Moderna

Pfizer

The meetings are a sign that the vaccines are moving closer to a possible authorization.

FDA panel to discuss Novavax Covid vaccine for adults, Pfizer and Moderna shots for kids in June

NVX-CoV2373 would be the first protein-based COVID-19 vaccine to be reviewed by VRBPAC in the U.S. GAITHERSBURG, Md. , April 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 at a meeting scheduled for June 7, 2022.

FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine

Shares of Novavax Inc. NVAX, +13.62% jumped 10.8% in trading on Friday after the Food and Drug Administration announced that an advisory committee is set to meet June 7 to examine the benefits and risks of the company's experimental COVID-19 vaccine. Novavax's protein-based vaccine has been authorized in several countries, including by the U.K. and the European Commission, but is still being reviewed by the FDA.

FDA advisory committee to review Novavax's COVID-19 vaccine candidate in June

NVAX stock has become speculative, but it still has multiple ways to win. The company needs to step up its marketing game.

Novavax Stock Is Now Speculative, But it Still Has a Shot

Is demand running out for COVID-19 vaccines?

This Could Spell Bad News for Novavax

Novavax recently got Nuvaxovid approved for use in Japan for both primary and booster shots. It's done nothing for NVAX stock.

Novavax Could Get Analyst Downgrades Leading Up to Earnings

Cazoo Group Ltd

Ginkgo Bioworks Holdings

Lottery.com

Netflix

Shopify

Sonder Holdings

While going contrarian is always a risky concept, these biggest loser stocks could bounce higher with the negativity priced in. The post 7 Biggest Loser Stocks That Could Become Surprising Buys appeared first on InvestorPlace.

7 Biggest Loser Stocks That Could Become Surprising Buys

This beaten-down vaccine stock appears to be dirt cheap right now.

Down 80% From Its High, Is Novavax Stock a Smart Buy Now?

Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.

Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents

Shares of vaccine companies, including Novavax, Inc. (NASDAQ: NVAX), are trading higher amid COVID-19 concerns due to rising cases in China. Rising COVID-19 cases in China's capital Beijing and Shanghai, where enforcement of a strict "zero-COVID" policy is ongoing, have drawn global.

Why Novavax Shares Are Rising

The approval of Novavax's COVID vaccine in Japan would be more notable had the company's 2021 vaccine rollout gone according to plan.

Does Novavax's Latest Approval Change Anything for Shareholders?

Axsome Therapeutics

Novocure

These Fool.com contributors see happy news in the future for Novavax, Axsome Therapeutics, and Novocure.

The FDA Will Soon Give These 3 Healthcare Companies the Green Light

American Airlines

Advisorshares Hotel ETF

Defiance Hotel Airline and Cruise ETF

Advisorshares Restaurant ETF

US Global Jets ETF

ALPS Global Travel Beneficiaries ETF

SonicShares Airlines, Hotels, Cruise Lines ETF

As the pandemic is slowly turning into an endemic, leisure and travel stocks have flied higher.

Time for Reopening-Friendly Travel & Leisure ETFs?

While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. The post Novavax Stock Could Give Back More of Its Pandemic-Era Gains appeared first on InvestorPlace.

Novavax Stock Could Give Back More of Its Pandemic-Era Gains

PREVENT-19 trial participants aged 12 through 17 receive third dose of NVX-CoV2373 Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose GAITHERSBURG, Md. , April 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has initiated administration of the first booster doses of NVX-CoV2373, the company's protein-based COVID-19 vaccine, in the pediatric expansion of the PREVENT-19 pivotal Phase 3 clinical trial.

Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial

Since my last bullish note on Novavax, the company's stock is down >60%, to $52, and a market cap valuation of $3.95bn. This seems absurdly low when we consider management is guiding for $4-$5bn revenues in 2022 and is likely to drive high profit margins.

Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull Case

Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.

Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study

It hasn't been all smooth sailing for this biotech company.

Is Novavax Stock in Trouble?

NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials. The post Novavax Stock Looks Like a Good Value With Its New Combined Vaccine appeared first on InvestorPlace.

Novavax Stock Looks Like a Good Value With Its New Combined Vaccine

Preliminary results from an early clinical study show the combined shot could be safe and effective.

Novavax Stock Is Down Despite Positive Initial Data for First Covid and Flu Shot

Wilmington, Delaware--(Newsfile Corp. - April 20, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Novavax, Inc. (NASDAQ: NVAX) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-novavax-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Novavax, Inc.

The company's combination COVID/flu jab performs well in a clinical trial.

Why Novavax Stock Fell Today Even After Good News

Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed in stand-alone influenza vaccine and combination vaccine with potential path forward for both GAITHERSBURG, Md. , April 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC).

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

Novavax plans to move forward with a phase two trial this year to confirm the dosing levels, and a phase three during the 2023 flu season at the earliest.

Novavax says vaccine targeting Covid and flu shows promising results in early data

Novavax is late to the Covid-19 vaccine race and is up against some stiff competition. NVAX stock is in a tough spot.

News for Novavax Stock (NVAX)